{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:35:29Z","timestamp":1768566929023,"version":"3.49.0"},"posted":{"date-parts":[[2025,1,20]]},"group-title":"Oncology","reference-count":28,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anatomical surgical resection is the treatment of choice for early-stage non\u2013small cell lung cancer (NSCLC) and is a part of the multimodality treatment for resectable, locally advanced NSCLC. Local, regional and distant recurrence is the most common cause of treatment failure after resection. Multiple studies have recommended chest computed tomography (CT) for lung cancer (LC) patient\u2019s follow-up. Even though adopting this strategy, the recurrence will only be detected months after the onset of the disease once imaging changes will only occur with a high tumor burden.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Breath analysis is a promising technology and useful addition to the currently available modalities to achieve lung cancer diagnosis and management. The volatile organic compounds (VOCs) produced as end-products of metabolism by the LC cells (and present on the exhaled breath of the patients) seem to have a unique pattern that can be used as a tool to detect lung cancer (VOC profile).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The BREATH-PATH study aims to establish a VOC profile for all LC patients at diagnosis and understand its variations with the different implemented treatments in order to find response patterns. By understanding these patterns and identifying their deviations thereof with disease relapse supported by imaging methods we will be able to validate the breath analysis as a useful tool for LC recurrence detection.<\/jats:p>\n                  <jats:p>This study intents not only to reiterate the methods\u2019 efficacy but also to understand how high its sensitivity is in detecting a tumor recurrence, allowing breath analysis to be integrated into clinical decision algorithms.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.01.19.25320800","type":"posted-content","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T02:40:17Z","timestamp":1737427217000},"source":"Crossref","is-referenced-by-count":0,"title":["BREATH-PATH \u2013 Protocol for lung cancer management in surgical patients through analysis of breath profiles"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-1364","authenticated-orcid":false,"given":"Rita","family":"Barata","sequence":"first","affiliation":[]},{"given":"Catarina","family":"Carvalheiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8154-3872","authenticated-orcid":false,"given":"Bernardo S.","family":"Raimundo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-8069","authenticated-orcid":false,"given":"Marcos","family":"Pantarotto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-9801","authenticated-orcid":false,"given":"Pedro D.","family":"Vaz","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2025012209151348000_2025.01.19.25320800v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"issue":"6","key":"2025012209151348000_2025.01.19.25320800v1.2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or Sublobar Resection for Peripheral Stage IA Non\u2013Small-Cell Lung Cancer","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"10335","key":"2025012209151348000_2025.01.19.25320800v1.3","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","year":"2022","journal-title":"The Lancet"},{"key":"2025012209151348000_2025.01.19.25320800v1.4","unstructured":"Postmus PE . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up."},{"key":"2025012209151348000_2025.01.19.25320800v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1994"},{"key":"2025012209151348000_2025.01.19.25320800v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594"},{"key":"2025012209151348000_2025.01.19.25320800v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983"},{"key":"2025012209151348000_2025.01.19.25320800v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"issue":"6","key":"2025012209151348000_2025.01.19.25320800v1.9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJMc2407267","volume":"391","author":"Perioperative Nivolumab in Resectable Lung Cancer","year":"2024","journal-title":"N Engl J Med"},{"key":"2025012209151348000_2025.01.19.25320800v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875"},{"issue":"10308","key":"2025012209151348000_2025.01.19.25320800v1.11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","year":"2021","journal-title":"The Lancet"},{"key":"2025012209151348000_2025.01.19.25320800v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6"},{"key":"2025012209151348000_2025.01.19.25320800v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532"},{"issue":"4","key":"2025012209151348000_2025.01.19.25320800v1.14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.athoracsur.2023.06.004","article-title":"Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial","volume":"116","year":"2023","journal-title":"The Annals of Thoracic Surgery"},{"key":"2025012209151348000_2025.01.19.25320800v1.15","unstructured":"Uramoto H , Tanaka F. Recurrence after surgery in patients with NSCLC. Translational lung cancer research. 2014;3(4)."},{"issue":"4","key":"2025012209151348000_2025.01.19.25320800v1.16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013Small Cell Lung Cancer, Version 4.2024","volume":"22","year":"2024","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"9","key":"2025012209151348000_2025.01.19.25320800v1.17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(22)00451-X","article-title":"Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial","volume":"23","year":"2022","journal-title":"The Lancet Oncology"},{"key":"2025012209151348000_2025.01.19.25320800v1.18","unstructured":"van Meerbeeck JP , Sirimsi H. Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer. Translational lung cancer research. 2015;4(4)."},{"key":"2025012209151348000_2025.01.19.25320800v1.19","doi-asserted-by":"crossref","unstructured":"Mitchell J , Benamore R , Gleeson F , Belcher E. Computed tomography follow-up identifies radically treatable new primaries after resection for lung cancer. European Journal of Cardio-Thoracic Surgery. 2019 Oct 25;ezz284.","DOI":"10.1093\/ejcts\/ezz284"},{"issue":"2","key":"2025012209151348000_2025.01.19.25320800v1.20","doi-asserted-by":"crossref","first-page":"027111","DOI":"10.1088\/1752-7163\/aa9386","article-title":"Diagnostic biomarkers for lung cancer prevention","volume":"12","year":"2018","journal-title":"J Breath Res"},{"issue":"6","key":"2025012209151348000_2025.01.19.25320800v1.21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2016.02.017","article-title":"Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer","volume":"11","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"issue":"7","key":"2025012209151348000_2025.01.19.25320800v1.22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jtho.2018.02.026","article-title":"Breathprinting and Early Diagnosis of Lung Cancer","volume":"13","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"key":"2025012209151348000_2025.01.19.25320800v1.23","doi-asserted-by":"crossref","unstructured":"Issitt T , Wiggins L , Veysey M , Sweeney ST , Brackenbury WJ , Redeker K. Volatile compounds in human breath: critical review and meta-analysis. J Breath Res. 2022 Feb 23;16(2).","DOI":"10.1088\/1752-7163\/ac5230"},{"issue":"1","key":"2025012209151348000_2025.01.19.25320800v1.24","doi-asserted-by":"crossref","first-page":"e182815","DOI":"10.1001\/jamaoncol.2018.2815","article-title":"Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025012209151348000_2025.01.19.25320800v1.25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2022.12.003","article-title":"Mapping the landscape of lung cancer breath analysis: A scoping review (ELCABA)","volume":"175","year":"2023","journal-title":"Lung Cancer"},{"issue":"12","key":"2025012209151348000_2025.01.19.25320800v1.26","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3390\/cancers16122200","article-title":"AI Applied to Volatile Organic Compound (VOC) Profiles from Exhaled Breath Air for Early Detection of Lung Cancer","volume":"16","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"2025012209151348000_2025.01.19.25320800v1.27","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.3390\/curroncol29100578","article-title":"The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?","volume":"29","year":"2022","journal-title":"Current Oncology"},{"issue":"3","key":"2025012209151348000_2025.01.19.25320800v1.28","doi-asserted-by":"crossref","first-page":"030401","DOI":"10.1088\/1752-7163\/ad3fdf","article-title":"Establishing breath as a biomarker platform\u2014take home messages from the Breath Biopsy Conference 2023","volume":"18","year":"2024","journal-title":"J Breath Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.01.19.25320800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:25:53Z","timestamp":1768508753000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.01.19.25320800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1101\/2025.01.19.25320800","relation":{},"subject":[],"published":{"date-parts":[[2025,1,20]]},"subtype":"preprint"}}